<div id="readability-page-1"><ul><li>Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead</li></ul><p>Septerna, Inc. (NASDAQ:SEPN - Free Report) - Equities researchers at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Septerna in a report issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.53) for the year, down from their previous forecast of ($1.45). HC Wainwright has a &#34;Buy&#34; rating and a $35.00 price objective on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna's Q4 2025 earnings at ($0.16) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.61) EPS and FY2026 earnings at ($1.67) EPS.</p><p>SEPN has been the topic of several other research reports. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Septerna in a research report on Wednesday, October 8th. Raymond James Financial initiated coverage on Septerna in a report on Friday, December 19th. They issued a &#34;strong-buy&#34; rating and a $38.00 price objective on the stock. Wells Fargo &amp; Company raised Septerna from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and lifted their target price for the stock from $18.00 to $28.00 in a report on Friday, November 14th. Truist Financial initiated coverage on shares of Septerna in a research report on Monday, December 15th. They issued a &#34;buy&#34; rating and a $34.00 target price for the company. Finally, Wall Street Zen lowered shares of Septerna from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, January 10th. One analyst  has rated the stock with a Strong Buy rating, five have assigned  a Buy rating and one  has assigned  a Sell rating to the stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and an average target price of $33.83.</p><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p><b>Check Out Our Latest Research Report on Septerna</b></p><h2>Septerna Stock Down 2.5%</h2><p>Septerna stock opened at $26.35 on Thursday. The company's 50-day moving average price is $26.56 and its two-hundred day moving average price is $19.60. The stock has a market cap of $1.18 billion, a P/E ratio of -17.45 and a beta of 3.85. Septerna has a twelve month low of $4.17 and a twelve month high of $30.50. </p><ul><li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li></ul><p>Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28). The company had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. </p><h2>Institutional Investors Weigh In On Septerna</h2><p>Several institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in  Septerna during the third quarter worth about $36,000.  Covestor Ltd lifted its holdings in shares of  Septerna by 55.8% during the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company's stock worth $68,000 after acquiring an additional 1,296 shares during the period.  BNP Paribas Financial Markets boosted its position in shares of  Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company's stock worth $78,000 after acquiring an additional 1,945 shares in the last quarter.  JPMorgan Chase &amp; Co. increased its stake in  Septerna by 15.0% in the second quarter. JPMorgan Chase &amp; Co. now owns 10,101 shares of the company's stock valued at $107,000 after acquiring an additional 1,315 shares during the last quarter.  Finally, PharVision Advisers LLC acquired a new position in  Septerna during the second quarter valued at approximately $107,000. </p><h2>Insider Buying and Selling at Septerna</h2><p>In other news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total transaction of $63,228.06. Following the sale, the senior vice president directly owned 92,911 shares of the company's stock, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own  4.30% of the company's stock. </p><h2>About Septerna</h2> (Get Free Report)<p>We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Septerna</li><li>Wall Street Alert: Buy AES</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>New gold price target</li><li>Trump Did WHAT??</li><li>Melt-up warning</li></ul> <p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Septerna Right Now?</h2><p>Before you consider Septerna, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.</p><p>While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>HC Wainwright has revised its FY2025 earnings per share (EPS) estimate for Septerna, Inc. (NASDAQ:SEPN) from ($1.45) to ($1.53). The analyst maintains a "Buy" rating with a price target of $35.00. The consensus estimate for Septerna's full-year earnings is ($7.11) per share. The stock has seen various ratings, with one strong buy, five buys, and one sell. Septerna's stock opened at $26.35, down 2.5%, with a market cap of $1.18 billion. Recent quarterly earnings reported a loss of ($0.09) per share, missing estimates.</p>

Market Beat

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Septerna

VG Health

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

HC Wainwright Issues Negative Forecast for Septerna Earnings